Growth in China helps keep Novartis from the patent cliff
Switzerland-based Novartis is one of a number of leading global pharma companies that has reason to worry about the patent cliff: its top-selling product, hypertension drug Diovan, comes off patent in September. However, the company has just…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.